Akero Therapeutics
Akero fails to meet NASH trial endpoint, hurting other players in the field
Anika Sharma
The landscape of Nonalcoholic Steatohepatitis (NASH) appeared promising with Madrigal Therapeutics taking steps toward treatment approval. However, this optimism was ...
Akero Therapeutics’ shares plummet after phase 2b trial of NASH drug fails to improve cirrhosis
Anika Sharma
Akero Therapeutics, a leading contender in the nonalcoholic steatohepatitis (NASH) field, has encountered a setback as its FGF21 analog, efruxifermin ...
